Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126694361 | 12669436 | 1 | I | 20160808 | 20160819 | 20160819 | EXP | US-PFIZER INC-2016381090 | PFIZER | 70.00 | YR | M | Y | 90.25000 | KG | 20160819 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126694361 | 12669436 | 1 | PS | CYTARABINE. | CYTARABINE | 1 | UNK | U | 72168 | SOLUTION FOR INJECTION | |||||||||
| 126694361 | 12669436 | 2 | SS | DECITABINE. | DECITABINE | 1 | UNK | U | 0 | ||||||||||
| 126694361 | 12669436 | 3 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | Oral | 325 MG, AS NEEDED, (TAKE 1 TAB BY MOUTH EVERY 6 HOURS AS NEEDED FOR PAIN) | 0 | 325 | MG | TABLET | |||||||
| 126694361 | 12669436 | 4 | C | AUGMENTIN | AMOXICILLINCLAVULANATE POTASSIUM | 1 | Oral | 1 DF, 2X/DAY, AMOXICILLIN SODIUM: 875 MG, CLAVULANATE POTASSIUM:125MG | 0 | 1 | DF | BID | |||||||
| 126694361 | 12669436 | 5 | C | VITAMIN C | ASCORBIC ACID | 1 | Oral | 500 MG, UNK | 0 | 500 | MG | CAPSULE | |||||||
| 126694361 | 12669436 | 6 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG, DAILY | 0 | 81 | MG | MODIFIED-RELEASE TABLET | |||||||
| 126694361 | 12669436 | 7 | C | BUDESONIDE. | BUDESONIDE | 1 | Respiratory (inhalation) | 0.25 MG, DAILY, (0.25 MG/2ML) | 0 | .25 | MG | ||||||||
| 126694361 | 12669436 | 8 | C | CHLORDIAZEPOXIDE HYDROCHLORIDE W/CLIDINIUM | 2 | Oral | UNK, CHLORDIAZEPOXIDE HYDROCHLORIDE 5MG, CLIDINIUM 2.5MG | 0 | CAPSULE | ||||||||||
| 126694361 | 12669436 | 9 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 2000 IU, UNK | 0 | 2000 | IU | TABLET | |||||||
| 126694361 | 12669436 | 10 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 75 MG, DAILY | 0 | 75 | MG | TABLET | ||||||||
| 126694361 | 12669436 | 11 | C | DICYCLOMINE HCL | DICYCLOMINE HYDROCHLORIDE | 1 | 10 MG, 4X/DAY, (TAKE 1 CAP BY MOUTH 4 TIMES DAILY (BEFORE MEALS AND NIGHTLY)) | 0 | 10 | MG | CAPSULE | QID | |||||||
| 126694361 | 12669436 | 12 | C | DOCUSATE SODIUM. | DOCUSATE SODIUM | 1 | Oral | 100 MG, AS NEEDED, (TAKE 100 MG BY MOUTH 2 TIMES DAILY AS NEEDED FOR CONSTIPATIN) | 0 | 100 | MG | CAPSULE | |||||||
| 126694361 | 12669436 | 13 | C | FAMOTIDINE. | FAMOTIDINE | 1 | Oral | 20 MG, UNK | 0 | 20 | MG | TABLET | |||||||
| 126694361 | 12669436 | 14 | C | FLUCONAZOLE. | FLUCONAZOLE | 1 | Oral | 200 MG, 1X/DAY | 0 | 200 | MG | TABLET | QD | ||||||
| 126694361 | 12669436 | 15 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 20 MG, UNK | 0 | 20 | MG | TABLET | |||||||
| 126694361 | 12669436 | 16 | C | HYDRALAZINE HCL | HYDRALAZINE HYDROCHLORIDE | 1 | Oral | 50 MG, 3X/DAY, (TAKE 1 TAB BY MOUTH 3 TIMES DAILY) | 0 | 50 | MG | TABLET | TID | ||||||
| 126694361 | 12669436 | 17 | C | INSULIN ASPART | INSULIN ASPART | 1 | Subcutaneous | 100 IU/ML, UNK, (LNJECT UNDER THE SKIN) | 0 | SOLUTION FOR INJECTION | |||||||||
| 126694361 | 12669436 | 18 | C | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Subcutaneous | 100 IU/ML, UNK, (LNJECT UNDER THE SKIN) | 0 | SOLUTION FOR INJECTION | |||||||||
| 126694361 | 12669436 | 19 | C | LEVOFLOXACIN. | LEVOFLOXACIN | 1 | Oral | 500 MG, 1X/DAY | 0 | 500 | MG | TABLET | QD | ||||||
| 126694361 | 12669436 | 20 | C | LORATADINE. | LORATADINE | 1 | Oral | 10 MG, AS NEEDED | 0 | 10 | MG | TABLET | |||||||
| 126694361 | 12669436 | 21 | C | METOPROLOL SUCCINATE. | METOPROLOL SUCCINATE | 1 | Oral | 50 MG, UNK, (50 MG TAB SR 24HR) | 0 | 50 | MG | MODIFIED-RELEASE TABLET | |||||||
| 126694361 | 12669436 | 22 | C | MONTELUKAST | MONTELUKAST SODIUM | 1 | Oral | 10 MG, UNK | 0 | 10 | MG | TABLET | |||||||
| 126694361 | 12669436 | 23 | C | NYSTATIN. | NYSTATIN | 1 | Oral | 50000 IU, 4X/DAY | 0 | 50000 | IU | QID | |||||||
| 126694361 | 12669436 | 24 | C | MIRALAX | POLYETHYLENE GLYCOL 3350 | 1 | Oral | UNK | 0 | ||||||||||
| 126694361 | 12669436 | 25 | C | PREGABALIN. | PREGABALIN | 1 | Oral | 75 MG, 1X/DAY (NIGHTLY) | 0 | 75 | MG | CAPSULE | QD | ||||||
| 126694361 | 12669436 | 26 | C | ROSUVASTATIN. | ROSUVASTATIN | 1 | Oral | 20 MG, UNK | 0 | 20 | MG | TABLET | |||||||
| 126694361 | 12669436 | 27 | C | SERTRALINE HCL | SERTRALINE HYDROCHLORIDE | 1 | Oral | 50 MG, 1X/DAY | 0 | 50 | MG | TABLET | QD | ||||||
| 126694361 | 12669436 | 28 | C | ZINC SULFATE | ZINC SULFATEINC SULFATE ANHYDROUS | 1 | Oral | 220 MG, UNK (220 (50 ZN) MG | 0 | 220 | MG | TABLET | |||||||
| 126694361 | 12669436 | 29 | C | LENALIDOMIDE | LENALIDOMIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126694361 | 12669436 | 1 | Acute myeloid leukaemia |
| 126694361 | 12669436 | 2 | Acute myeloid leukaemia |
| 126694361 | 12669436 | 3 | Pain |
| 126694361 | 12669436 | 12 | Constipation |
| 126694361 | 12669436 | 20 | Hypersensitivity |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126694361 | 12669436 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126694361 | 12669436 | Acute kidney injury | |
| 126694361 | 12669436 | Acute myeloid leukaemia | |
| 126694361 | 12669436 | Disease recurrence | |
| 126694361 | 12669436 | Dyspnoea exertional | |
| 126694361 | 12669436 | Fatigue | |
| 126694361 | 12669436 | Muscle spasms | |
| 126694361 | 12669436 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126694361 | 12669436 | 1 | 20160615 | 0 |